CymitQuimica logo

PD-184161

CAS:

Ref. TR-P218100

10mg
243.00€
50mg
887.00€
100mg
1,571.00€
PD-184161
TRC

    Product Information

    Name:PD-184161
    Controlled Product
    Synonyms:
    • 5-Bromo-2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluorobenzamide
    Brand:TRC
    Description:Applications PD-184161 is a novel mitogen-activated protein kinase kinase (MEK) inhibitor shown to exhibit antitumor effects and suppress MEK-extracellular signal-related kinase signaling activity and cell proliferation in human hepatocellular carcinoma cells and in human hepatocellular carcinoma xenografts. Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the packageReferences Yip-Schneider, M.T. et al.: J. Pharmacol. Exp. Therap., 329, 1063 (2009); Klein, P.J. et al.: Neoplasia, 8, 1 (2006); Yung, H.W. et al.: Biochem. Pharmacol., 68, 351 (2004);
    Notice:Our products are intended for lab use only. For any other use, please contact us.

    Chemical properties

    Molecular weight:557.5556
    Formula:C17H13BrClF2IN2O2
    Color/Form:Neat
    InChI:InChI=1S/C17H13BrClF2IN2O2/c18-11-6-10(17(25)24-26-7-8-1-2-8)16(15(21)14(11)20)23-13-4-3-9(22)5-12(13)19/h3-6,8,23H,1-2,7H2,(H,24,25)
    InChI key:InChIKey=VJNZMSLGVUSPCF-UHFFFAOYSA-N
    SMILES:O=C(NOCC1CC1)c1cc(Br)c(F)c(F)c1Nc1ccc(I)cc1Cl

    Technical inquiry about: PD-184161

    Please use instead the cart to request a quotation or an order

    If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
    ◻️
    CYMIT QUÍMICA, S.L. as responsible for the treatment will treat your data in order to respond to your queries or requests. You can access, rectify and delete your data, as well as exercise other rights by consulting the additional and detailed information on data protection in our Web Privacy Policy.
    * Mandatory fields.